Abstract LB-198: Phase I and molecular correlates study of oral rigosertib in patients with refractory metastatic head and neck cancer and advanced solid tumors.
Cancer Res (2013) 73 (8_Supplement): LB-198.
Currently there are no citedby results. Try again later.